SHE:300765

2 stories mentioning SHE:300765Updated 19m ago

Every FINWIRES story that references SHE:300765, newest first.

CSPC Innovation Pharmaceutical Subsidiary Gets Regulatory Nod for Cancer Drug Trial

CSPC Innovation Pharmaceutical (SHE:300765) unit CSPC Jushi Biopharmaceutical obtained the approval of China's medical products administrator to conduct clinical trials for SYS6041 in combination therapy for ovarian cancer.The potential indications for SYS6041 include solid tumors such as gynecological tumors and lung cancer, according to a Tuesday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 4% lower Tuesday.

SHE:300765

Asia25d ago

CSPC Innovation Pharma Gets China Nod for Psoriasis Drug

CSPC Innovation Pharmaceutical (SHE:300765, HKG:1093) received drug registration from China's medical products administrator for ustekinumab injection.The drug, branded as Enyike, is used to treat moderate to severe plaque psoriasis, according to Friday filings with the Shenzhen and Hong Kong bourses.

HKG:1093SHE:300765

Track with the FINWIRES app suite

FolioX

Track SHE:300765 in your portfolio

WheelAI

Analyze SHE:300765 options with the wheel strategy

StockInsider

See market sentiment on SHE:300765